Methanobrevibacter smithii Dominance
Archaea—single-celled organisms distinct from bacteria—comprise only ~0.1-1% of gut microbiota by abundance but have outsized importance. Methanobrevibacter smithii is the dominant archaeal species in ~90% of humans. Unlike bacteria, archaea employ alternative metabolic pathways suited to extreme environments, yet M. smithii thrives in the temperate colon.
Methanogenesis and Syntrophy
M. smithii catalyzes methanogenesis: converting hydrogen (H2) and carbon dioxide (CO2) into methane (CH4). This process follows complex fermentation by bacteria, creating a syntrophic relationship. Fermenting bacteria produce H2 and CO2; without H2 removal, their metabolism stalls (too much acetyl-CoA accumulates). Methanogens act as "hydrogen sinks," consuming H2 and re-energizing bacterial fermentation. This mutualism is crucial for fiber metabolism efficiency.
Clinical Implications: SIBO and IMO
Small intestinal bacterial overgrowth (SIBO) has a methanogenic variant: intestinal methanogen overgrowth (IMO), where methanogens multiply in the small bowel. Excess methane slows transit time by 25-40%, favoring further microbial expansion and symptom escalation (bloating, constipation). The hydrogen breath test detects methane; IMO is suggested by methane >12 ppm at fasting or early post-lactulose rise.
Methanogen-Associated Constipation
Epidemiology shows methane-positive breath tests correlate with IBS-C (constipation subtype). Methane production by methanogens directly impairs colonic motility. Rifaximin (minimally absorbed antibiotic) plus neomycin (reduces bacteria providing H2) targets methanogens, showing modest benefit in SIBO/IMO. However, methane producers are archaea, not bacteria, making antibiotics less effective; novel archaeal-targeting agents are under investigation.
Detection Challenges
Archaea are underrepresented in standard 16S rRNA sequencing (archaeal-specific primers are needed). Many microbiome studies miss archaea entirely. Breath testing (hydrogen and methane measurement) remains the clinical gold standard for detection, though it measures production capacity, not absolute numbers.